Asset acquisition vs. business combination (ASC 805)

ASC 805 defines a business as an integrated set of inputs and processes capable of producing outputs. The screen test comes first: if substantially all of the fair value acquired sits in a single identifiable asset or group of similar assets, the deal is an asset acquisition. Most preclinical and early clinical acquisitions fail the screen because the value is concentrated in one program.

The consequences diverge sharply. In a business combination, assets and liabilities are recorded at fair value, IPR&D is capitalized, goodwill can arise, contingent consideration is a liability remeasured through earnings each quarter, and transaction costs are expensed. In an asset acquisition, cost is allocated on a relative fair value basis, IPR&D is usually expensed, no goodwill arises, contingent payments are generally recognized when probable, and transaction costs are capitalized.

Because the two models produce different income statements from the same economics, the screen-test memo is one of the first documents an auditor requests after any acquisition.